Clinic
Dayton Pain Center LLC
Dayton Pain Center LLC was paid $3.41M by Medicaid between Jan 2018 and Nov 2024, across 49 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoDAYTON PAIN CENTER LLC
DAYTON, OH 45417
DAYTON, OH 45417
33aNPI1790730638assigned 05/22/2006
33bProvider typePain Clinic/Center
28Total paid$3.41M
24GClaims188,449
24DCodes billed49
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pain Clinic/Center providers in Ohio
Rank by total paid#3 of 8
Median peer was paid$239K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,354 | $718K | |
| 2019 | 32,679 | $536K | |
| 2020 | 33,106 | $588K | |
| 2021 | 17,480 | $542K | |
| 2022 | 16,251 | $471K | |
| 2023 | 14,479 | $328K | |
| 2024incomplete | 10,100 | $223K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 43,649 | 35,662 | $797K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 21% | 26,566 | 16,430 | $713K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 25,736 | 22,098 | $665K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 9.5% | 2,763 | 2,370 | $323K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.3% | 2,565 | 2,388 | $77K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.2% | 4,631 | 3,131 | $74K |
| 80346 | 1.7% | 3,483 | 2,574 | $56K | |
| 80362 | 1.4% | 3,482 | 2,573 | $48K | |
| 80361 | 1.4% | 3,483 | 2,574 | $48K | |
| 01992 | 1.3% | 909 | 771 | $43K | |
| 83992 | 1.1% | 3,492 | 2,586 | $38K | |
| 80373 | <1% | 3,482 | 2,574 | $32K |
37 more codes
| 80372 | <1% | 3,482 | $32K | |
| 80336 | <1% | 3,481 | $32K | |
| 80368 | <1% | 3,482 | $32K | |
| 80366 | <1% | 3,482 | $32K | |
| 80355 | <1% | 3,483 | $32K | |
| 80369 | <1% | 3,482 | $32K | |
| 80365 | <1% | 3,483 | $27K | |
| 80360 | <1% | 3,483 | $27K | |
| 80356 | <1% | 3,483 | $27K | |
| 80349 | <1% | 3,483 | $27K | |
| 80358 | <1% | 3,483 | $27K | |
| 80348 | <1% | 3,483 | $27K | |
| 80354 | <1% | 3,483 | $27K | |
| 80359 | <1% | 3,483 | $27K | |
| 80353 | <1% | 3,483 | $27K | |
| 80324 | <1% | 3,469 | $26K | |
| 80305 | <1% | 1,730 | $8K | |
| 77002 | <1% | 399 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 197 | $5K |
| 99205 | Prolong outpt/office vis | <1% | 58 | $4K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 165 | $3K |
| 62370 | <1% | 205 | $3K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 445 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 151 | $1K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $507.58 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 316 | $412.81 |
| 96130 | <1% | 28 | $291.72 | |
| 80335 | <1% | 3,473 | $212.73 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 339 | $175.14 |
| 77003 | <1% | 13 | $167.13 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 563 | $84.77 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 16 | $73.76 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 14 | $40.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 263 | $29.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 16 | $12.92 |
| A4220 | Refill kit for implantable infusion pump | 0% | 77 | $0.00 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREDDY, BHIMAVARAPU (MEDICAL DIRECTOR)